Engineered platelet-based immune engager for tumor post-surgery treatment

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Tumor metastasis and recurrence significantly contribute to cancer mortality and poor prognosis.
• Inefficient T cell-tumor cell engagement and immune checkpoints limit the immune system's surveillance of cancer cells.

Purpose of the Study:

• To develop an immune engager using engineered platelets to enhance T cell-mediated anti-tumor immunity.
• To evaluate the efficacy of platelet-based immune engagers combined with immune checkpoint blockade in preclinical cancer models.

Main Methods:

• Engineered platelets modified with CD3 antibodies (P-aCD3) were constructed to bridge T cells and tumor cells.
• The P-aCD3 construct was tested in combination with immune checkpoint blockade in mice with melanoma and breast cancer.
• Tumor recurrence, metastasis, and overall survival were assessed.

Main Results:

• P-aCD3 facilitated enhanced contact between T cells and tumor cells.
• The combination therapy significantly improved T cell-mediated cytotoxicity.
• Tumor recurrence and metastasis were effectively inhibited, leading to significantly prolonged survival in mice.

Conclusions:

• Engineered platelets with CD3 antibody modification serve as effective immune engagers.
• Combining P-aCD3 with immune checkpoint blockade offers a promising strategy to overcome immune evasion and improve cancer treatment outcomes.